Fermented Soybean Paste Attenuates Biogenic Amine-Induced Liver Damage in Obese Mice

Cells. 2023 Mar 6;12(5):822. doi: 10.3390/cells12050822.

Abstract

Biogenic amines are cellular components produced by the decarboxylation of amino acids; however, excessive biogenic amine production causes adverse health problems. The relationship between hepatic damage and biogenic amine levels in nonalcoholic fatty liver disease (NAFLD) remains unclear. In this study, mice were fed a high-fat diet (HFD) for 10 weeks to induce obesity, presenting early-stage of NAFLD. We administered histamine (20 mg/kg) + tyramine (100 mg/kg) via oral gavage for 6 days to mice with HFD-induced early-stage NAFLD. The results showed that combined histamine and tyramine administration increased cleaved PARP-1 and IL-1β in the liver, as well as MAO-A, total MAO, CRP, and AST/ALT levels. In contrast, the survival rate decreased in HFD-induced NAFLD mice. Treatment with manufactured or traditional fermented soybean paste decreased biogenically elevated hepatic cleaved PARP-1 and IL-1β expression and blood plasma MAO-A, CRP, and AST/ALT levels in HFD-induced NAFLD mice. Additionally, the biogenic amine-induced reduction in survival rate was alleviated by fermented soybean paste in HFD-induced NAFLD mice. These results show that biogenic amine-induced liver damage can be exacerbated by obesity and may adversely affect life conservation. However, fermented soybean paste can reduce biogenic amine-induced liver damage in NAFLD mice. These results suggest a beneficial effect of fermented soybean paste on biogenic amine-induced liver damage and provide a new research perspective on the relationship between biogenic amines and obesity.

Keywords: IL-1β; MAO; NAFLD; biogenic amine; liver; obesity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biogenic Amines
  • Fermented Foods*
  • Glycine max / chemistry
  • Histamine
  • Mice
  • Mice, Obese
  • Monoamine Oxidase
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • Obesity
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
  • Tyramine / therapeutic use

Substances

  • Histamine
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Biogenic Amines
  • Monoamine Oxidase
  • Tyramine

Grants and funding

This study was supported by grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (2020R1I1A306867013 and 2021R1A4A302712212); the Korea Research Institute of Bioscience and Biotechnology Research Initiative Program (KGM4562222); and the Research Program for Agricultural Science & Technology Development and the National Institute of Agricultural Sciences (PJ013833), Rural Development Administration, Republic of Korea.